The latest announcement is out from RemeGen Co. Ltd. Class H ( (HK:9995) ).
RemeGen Co., Ltd. announced that its Phase III study results for telitacicept, a dual-target fusion protein drug for treating generalized myasthenia gravis, have been selected for a major presentation at the 2025 American Academy of Neurology Annual Meeting. This recognition highlights the potential impact of telitacicept on the treatment landscape of neurological disorders, although there is no assurance of its successful market launch.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a pharmaceutical company based in China, focusing on the development of innovative drugs. The company specializes in creating fusion protein drugs, particularly targeting B-cell lymphocyte stimulator and proliferation-inducing ligand (BLyS/APRIL).
YTD Price Performance: 12.50%
Average Trading Volume: 2,398,796
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$14.44B
See more data about 9995 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com